SAP

246.35

+0.72%↑

ASML

596.4

-1.11%↓

DSY

27.8

-0.5%↓

STMPA.FR

21.57

-0.78%↓

NOKIA.FI

3.52

-0.28%↓

SAP

246.35

+0.72%↑

ASML

596.4

-1.11%↓

DSY

27.8

-0.5%↓

STMPA.FR

21.57

-0.78%↓

NOKIA.FI

3.52

-0.28%↓

SAP

246.35

+0.72%↑

ASML

596.4

-1.11%↓

DSY

27.8

-0.5%↓

STMPA.FR

21.57

-0.78%↓

NOKIA.FI

3.52

-0.28%↓

SAP

246.35

+0.72%↑

ASML

596.4

-1.11%↓

DSY

27.8

-0.5%↓

STMPA.FR

21.57

-0.78%↓

NOKIA.FI

3.52

-0.28%↓

SAP

246.35

+0.72%↑

ASML

596.4

-1.11%↓

DSY

27.8

-0.5%↓

STMPA.FR

21.57

-0.78%↓

NOKIA.FI

3.52

-0.28%↓

Search

Nemetschek SE

Cerrado

SectorTecnología

132.1 0.99

Resumen

Variación precio

24h

Actual

Mínimo

130.9

Máximo

134

Métricas clave

By Trading Economics

Ingresos

-11M

57M

Ventas

-8.1M

283M

P/B

Media del Sector

82.143

71.636

BPA

0.39

Rentabilidad por dividendo

0.43

Margen de beneficio

20.134

Empleados

3,994

EBITDA

-15M

81M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

-7.79% downside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.43%

2.51%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1.2B

15B

Apertura anterior

131.11

Cierre anterior

132.1

Noticias sobre sentimiento de mercado

By Acuity

39%

61%

148 / 407 Clasificación en Technology

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Nemetschek SE Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

4 ago 2025, 21:42 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 ago 2025, 21:21 UTC

Ganancias
Principales Movimientos del Mercado

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 ago 2025, 20:45 UTC

Ganancias

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 ago 2025, 19:15 UTC

Principales Movimientos del Mercado

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 ago 2025, 23:41 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 ago 2025, 23:41 UTC

Charlas de Mercado

Nikkei May Rise on Fed Stimulus Hopes

4 ago 2025, 23:28 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

4 ago 2025, 23:28 UTC

Charlas de Mercado

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 ago 2025, 21:30 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 ago 2025, 21:21 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 ago 2025, 21:18 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 ago 2025, 20:25 UTC

Charlas de Mercado

India Hits Back Over Russian Oil Purchases -- Market Talk

4 ago 2025, 20:25 UTC

Ganancias

Transocean 2Q Loss $938M >RIG

4 ago 2025, 20:25 UTC

Ganancias

Transocean 2Q Loss/Shr $1.06 >RIG

4 ago 2025, 20:18 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 ago 2025, 20:15 UTC

Ganancias

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 ago 2025, 20:13 UTC

Ganancias

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 ago 2025, 20:09 UTC

Ganancias

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 ago 2025, 20:06 UTC

Ganancias

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 ago 2025, 19:41 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 ago 2025, 19:28 UTC

Charlas de Mercado

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 ago 2025, 19:07 UTC

Charlas de Mercado

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 ago 2025, 18:27 UTC

Charlas de Mercado

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparación entre iguales

Cambio de precio

Nemetschek SE Esperado

Precio Objetivo

By TipRanks

-7.79% caída

Estimación a 12 meses

Media 120.7 EUR  -7.79%

Máximo 144 EUR

Mínimo 100 EUR

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Nemetschek SE Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

5

Comprar

5

Mantener

1

Vender

Puntuación técnica

By Trading Central

120.9 / 123Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

148 / 407 Clasificación en Tecnología

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Nemetschek SE

Nemetschek SE provides software solutions for architecture, engineering, construction, media, and entertainment markets in Germany, rest of Europe, the Americas, the Asia Pacific, and internationally. It operates through four segments: Design, Build, Manage, and Media. The Design segment offers software solutions primarily under the Allplan, Graphisoft, Solibri, Precast, Vectorworks, SCIA, dRofus, Frilo, and RISA brands for architects, designers, engineers, structural engineers, specialist planners, and landscape designers, as well as developers and general contractors. This segment provides building information modeling (BIM) solutions for computer aided design and computer aided engineering. The Build segment offers integrated complete 5D BIM solutions primarily under the Bluebeam brand that support bidding and awarding, invoicing, budgeting, scheduling, and cost calculation. This segment serves construction companies, developers, building supplies, and general contractors, as well as planning offices, architects, and civil engineers. The Manage segment provides solutions for building and infrastructure projects; professional property management; and offer modular and integrated software solutions for property, facility, and workplace management under the Spacewell brand. The Media segment offers software solutions under the Maxon name for rendering 3D modeling, animation, painting, and sculpting. This segment includes film and television studio, advertising studios, video game production, freelancing, graphic designing, and other related activities. Nemetschek SE was founded in 1963 and is headquartered in Munich, Germany.